Guggenheim lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $40 from $46 and keeps a Buy rating on the shares. The firm made “relatively modest adjustments” to its model following the Q4, but cites the company’s higher share count for its lowered price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- UNCY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- 3 Best Stocks to Buy Today, 3/18/2026, According to Top Analysts
- Positioning Oxylanthanum Carbonate for Category-Defining Growth via TDAPA Advantage, Regulatory Clarity, and Robust Shareholder Returns
- Unicycive Therapeutics management to meet with Piper Sandler
- Unicycive Therapeutics initiated with a Buy at WestPark Capital